Genedata and Roche Join Forces in Proteomics ProcessBASEL, Switzerland, February 14, 2008--Genedata, a leading provider of in silico solutions for the pharmaceutical and life sciences industries, today announced an agreement with Roche for the company`s Genedata Expressionist ® Refiner MS module. As integral part of the Genedata Expressionist platform for biomarker discovery, Refiner MS performs automated quality assessment and pre-processing of mass spectrometry based proteomics and metabolomics data. The module handles all MS data formats in a flexible high throughput process, providing real-time interactive data quality assessment and processing hundreds of chromatograms simultaneously.
This high flexibility/high throughput duality accounts for the value Refiner MS adds to Roche`s biomarker discovery and diagnostic strategy. Dr. Hanno Langen, Section Head Proteomics-Pathways-Functional Genomics in the Roche Molecular Medicine Laboratories in Basel, explains, “Thanks to its open architecture, Refiner MS can be easily positioned in our lab workflows, allowing for optimal integration. The high performance qualities make it a key element in our proteomics process, for which the processing of large datasets is fundamental.”
“We are proud to support Roche in further developing their biomarker discovery operations,” says Dr. Othmar Pfannes, CEO of Genedata AG. “The successful positioning of Refiner MS in such a complex, multifaceted environment validates its excellent suitability for modern proteomics applications.”
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at www.roche.com.
Genedata specializes in software and professional services for pharmaceuticals, biotech and related life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data, Genedata Screener® for high throughput screening analysis, and Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and subsidiaries in Tokyo (Japan), Munich (Germany), Konstanz (Germany), Boston (USA) and San Francisco (USA). For more information about Genedata, please visit www.genedata.com
Disclaimer: The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Posted: February 2008